Orthobiologics and regenerative medicine are related terms, but they are not exact synonyms. Orthobiologics refers more specifically to biologic substances used in musculoskeletal and orthopedic care. Regenerative medicine is a broader field that includes approaches involving cells, tissues, biologic materials, and other technologies being studied or used across many areas of medicine.
That distinction matters because terms such as PRP, BMAC, stem cells, biologics, and exosomes are sometimes grouped together in marketing even though they differ substantially in composition, evidence, regulatory status, and intended use.
The American Academy of Orthopaedic Surgeons, or AAOS, describes orthobiologics as biologic substances used in orthopedic care and notes that the term is also commonly associated with orthopedic regenerative medicine.
Understanding the terminology can make it easier to ask informed questions before considering any treatment.
Are Orthobiologics and Regenerative Medicine the Same Thing?
Not exactly.
Think of regenerative medicine as the larger category and orthobiologics as one area within that category that focuses specifically on the musculoskeletal system.
Orthobiologics may be discussed in connection with bones, joints, cartilage, muscles, tendons, and ligaments. Regenerative medicine can extend well beyond orthopedics into research involving neurological, cardiovascular, ophthalmologic, hematologic, and other medical fields.
AAOS specifically uses the term orthobiologics for biologic substances used in orthopedic care, including blood-derived products such as platelet-rich plasma.
For patients exploring regenerative medicine and its terminology, recognizing this difference helps prevent very different treatments from being treated as though they belong in one interchangeable category.
Why the Terminology Becomes Confusing
The terminology is confusing partly because there isn’t one single procedure called “regenerative medicine.”
Instead, the phrase may refer to a broad group of technologies, biologic preparations, investigational products, and treatment approaches.
An orthopedic practice might discuss PRP as an orthobiologic. Another clinic might market a donor-derived cellular product as regenerative medicine. A third may use “stem cell therapy” to describe a bone marrow preparation.
Those descriptions can make the treatments sound more similar than they actually are.
Three questions help clarify what is being discussed:
- What material is being used?
- Where does that material come from?
- How is it processed before it is administered?
A fourth question is equally important: What evidence supports that specific product for the specific condition being treated?
Broad labels alone cannot answer those questions.
What Counts as an Orthobiologic?
Orthobiologics are biologic materials used within musculoskeletal care. Depending on the clinical context, the category may include blood-derived preparations, bone-related materials, cellular preparations, and other biologic substances.
AAOS lists examples that include platelet-rich plasma, autologous blood products, bone grafts, autologous conditioned serum, and certain cell-based approaches.
The important point is that “orthobiologic” describes a category rather than a single standardized treatment.
Two patients may both be told they are receiving an orthobiologic while receiving very different preparations.
Platelet-Rich Plasma
PRP is made from the patient’s own blood. Blood is collected and processed, usually through centrifugation, to create plasma containing a higher concentration of platelets.
Platelets participate in clotting and contain signaling proteins associated with tissue repair processes. PRP has been studied in several orthopedic conditions, although evidence and expected benefit vary depending on the injury, joint, preparation method, and patient.
Bone Marrow Aspirate Concentrate
Bone marrow aspirate concentrate, commonly called BMAC, begins with bone marrow collected from the patient. The aspirate is then processed to concentrate selected components.
BMAC contains a mixture of cells and other biologically active components. It should not automatically be described as a purified or laboratory-expanded stem cell treatment.
That distinction is important because a bone marrow concentrate and an isolated cell product are not the same material.
Cell-Based Products
Some products contain or are marketed as containing living cells. Their source, processing, intended use, and regulatory status can differ substantially.
Terms such as “stem cells” therefore need more explanation than the label itself provides.
PRP vs. BMAC vs. Stem Cell Products
The differences become easier to understand when the preparations are compared directly.
| Treatment Term | Typical Source | What It Generally Refers To | Key Distinction |
|---|---|---|---|
| PRP | Patient’s blood | Plasma concentrated with platelets | Blood-derived orthobiologic |
| BMAC | Patient’s bone marrow | Concentrated bone marrow aspirate containing multiple cell types and biologic components | Not the same as a purified stem cell product |
| Stem cell product | Source varies | Product containing or marketed as containing stem or progenitor cells | Regulatory status and processing require careful review |
| Donor-derived product | Another person or birth tissue source | Human cell or tissue-derived material | Different safety and regulatory considerations from autologous preparations |
| Exosome product | Cellular or laboratory source | Product marketed as containing extracellular vesicles called exosomes | FDA states there are currently no FDA-approved exosome products |
The name of a treatment doesn’t provide enough information to judge its evidence, safety, or regulatory status.
Patients should ask exactly what is being administered rather than relying on umbrella terms.
Why BMAC Should Not Automatically Be Called “Stem Cell Therapy”
Bone marrow contains several types of cells, including a small population of progenitor cells. A concentrated bone marrow preparation may therefore contain cells that are relevant to regenerative medicine research.
That does not mean BMAC is equivalent to an isolated, cultured, or purified stem cell product.
Calling every bone marrow preparation a “stem cell injection” can create an expectation that large numbers of stem cells are being injected specifically to rebuild cartilage or create new tissue. Current orthopedic evidence does not justify promising that outcome.
AAOS notes that the original idea that injected stem cells simply survive, multiply, and rebuild damaged orthopedic tissue has not been established. Current research continues to examine how cell-based preparations may influence signaling and local biological responses.
This distinction is one reason regenerative orthopedic medicine should be discussed in terms of the specific treatment, diagnosis, evidence, and clinical objective rather than broad regenerative claims.
Donor-Derived Products and Exosomes Belong in a Different Conversation
Autologous PRP and BMAC begin with material obtained from the patient. Donor-derived products originate from another human source and may include products marketed as coming from umbilical cord tissue, Wharton’s jelly, placental tissue, or other sources.
Exosome products are different again.
The FDA states that there are currently no FDA-approved exosome products. The agency has also warned about unapproved human cell and tissue products and has reported safety concerns involving products marketed as regenerative therapies.
A treatment being described as “natural,” “biologic,” “donor-derived,” or “regenerative” does not establish that it is FDA-approved or proven effective.
Patients considering these products should ask for the exact product name, manufacturer, source, processing method, regulatory status, and supporting clinical evidence.
What Does the FDA Say About Regenerative Medicine for Orthopedic Conditions?
This is one of the most important distinctions in the discussion.
The FDA states that regenerative medicine therapies have not been approved for the treatment of orthopedic conditions such as osteoarthritis, tendonitis, disc disease, back pain, knee pain, hip pain, neck pain, or shoulder pain.
The FDA also states that the only stem cell products currently approved in the United States consist of certain blood-forming stem cells derived from umbilical cord blood for disorders affecting blood production. Those approvals do not extend to orthopedic treatment.
This doesn’t mean that every procedure involving a patient’s own blood or bone marrow is legally identical to an unapproved commercial stem cell product. Regulation depends on characteristics such as the source, processing, manipulation, and intended use.
It does mean patients should be cautious when a treatment is marketed as FDA-approved stem cell therapy for arthritis, cartilage regeneration, or another orthopedic condition.
If FDA status is unclear, the patient can ask the treating physician to explain exactly how the product is regulated and what evidence applies to the proposed use.
Does “Regenerative” Mean the Treatment Regrows Cartilage or Tissue?
No.
The word regenerative can easily create the impression that a treatment has been shown to rebuild normal cartilage, regenerate tendons, restore discs, or permanently reverse degeneration.
That conclusion should not be assumed from the terminology.
Some orthobiologic therapies are investigated for effects on pain, function, inflammation, healing responses, or biological signaling. Those outcomes are different from proving that normal tissue has been restored.
AAOS notes that evidence for biologic therapies differs considerably across orthopedic conditions, with rigorous evidence still limited for many applications.
A responsible treatment discussion should separate several possible questions:
- Could symptoms improve?
- Could function improve?
- Is structural healing expected?
- Has tissue regeneration actually been demonstrated?
- How strong is the evidence for this particular diagnosis?
- How long have outcomes been studied?
- What alternatives are available?
Improvement in pain does not automatically prove cartilage regrowth, and a favorable imaging finding does not automatically mean a patient will experience better function.
Evidence Depends on the Specific Treatment and Diagnosis
There is no single evidence rating for “orthobiologics.”
Evidence for PRP in one condition cannot simply be transferred to BMAC in another condition. Likewise, evidence involving one preparation cannot automatically support a different product sold under a similar regenerative label.
AAOS reviews PRP and concentrated bone marrow aspirate separately because they are different interventions with different bodies of evidence.
PRP, for example, has been studied extensively in knee osteoarthritis and several tendon disorders. Results differ according to the condition and how the PRP is prepared.
Cell-based approaches remain an active area of research, but AAOS cautions that strong evidence supporting stem cell treatments for orthopedic conditions remains limited.
A useful question isn’t simply, “Does regenerative medicine work?”
A better question is:
What evidence supports this exact preparation for a patient with this exact diagnosis?
That produces a much more clinically meaningful discussion.
Orthobiologics Are Not Automatically a Replacement for Surgery
Orthobiologic treatments are often discussed with people who are interested in nonsurgical options. That doesn’t mean they can reliably prevent surgery.
The appropriate treatment depends on the diagnosis, severity of structural damage, symptoms, physical examination, imaging findings, previous treatments, health history, activity goals, and other patient-specific factors.
For one person, conservative treatment may remain appropriate. Another patient may have advanced structural damage for which surgery deserves serious consideration.
Statements such as “this treatment eliminates the need for joint replacement” or “stem cells can rebuild your joint so surgery will never be necessary” go beyond what current evidence supports.
A more useful goal is to understand where a biologic option might fit within the broader orthopedic treatment plan.
Questions to Ask Before Considering an Orthobiologic Treatment
Patients do not need to become experts in cell biology, but they should be able to receive clear answers about what is being offered.
Consider asking:
What exactly is being injected?
Ask for the precise preparation rather than accepting a general term such as regenerative injection or stem cell treatment.
Is it taken from my own body or from a donor?
The source affects what the treatment contains and may affect its regulatory and safety considerations.
How is the material processed?
PRP, concentrated bone marrow, laboratory-expanded cells, donor-derived tissue products, and exosome products are not interchangeable.
What evidence supports its use for my diagnosis?
Research involving a different joint or disease should not automatically be treated as evidence for your condition.
What outcome are we trying to achieve?
Clarify whether the goal is reducing symptoms, supporting function, assisting healing, delaying another intervention, or something else.
What are the realistic limitations?
Ask what the treatment has not been shown to do. This is particularly useful when claims involve cartilage regrowth or permanent tissue regeneration.
What are the risks and alternatives?
A balanced discussion should include conservative treatment, rehabilitation, medications when appropriate, injections, surgery when clinically indicated, and the option of doing nothing immediately.
What is the FDA status?
If the treatment involves a product marketed as containing stem cells, donor cells, birth tissue, or exosomes, ask the physician to explain its regulatory status before treatment.
Making Sense of the Terminology Before Choosing a Treatment
Orthobiologics and regenerative medicine overlap, but using the terms interchangeably can hide meaningful differences between treatments.
Orthobiologics generally describes biologic approaches used within orthopedic and musculoskeletal medicine. Regenerative medicine is broader and includes a much wider range of research, products, and medical applications.
Within orthopedics, PRP, autologous BMAC, donor-derived products, stem cell products, and exosomes should not be treated as though they are the same intervention. Their sources, processing, evidence, risks, and regulatory status differ.
The most useful approach is to start with a confirmed diagnosis, identify the exact treatment being proposed, review the evidence for that treatment and condition, and discuss realistic expectations with a qualified physician.
For patients comparing conservative, biologic, and other musculoskeletal care options, explore orthopedic treatment options and discuss which approaches may be appropriate after an individual medical evaluation.